A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Phase 1

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug: SEP-363856

• Registration Number: NCT05402111
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia. This study is accepting both male and female subjects. It will be conducted in approximately 6 study sites in the United States. The duration of participation will be approximtely 10 weeks.

Detailed Description

This is a randomized, open-label, single dose two-period crossover study with two treatment sequences. For each treatment sequence, subjects will receive a single-dose of SEP-363856 and prior antipsychotic (PA) standard of care (PA) in random order. Up to 3 separate cohorts of subjects will be randomized to determine the final dose of SEP-363856.

Study Timeline

• Study First Submitted: 2022-05-24
• Study First Submitted QC: 2022-05-27
• Study First Posted: 2022-06-02
• Study Start: 2022-06-13
• Primary Completion: 2023-09-27
• Study Completion: 2023-09-27
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-25
• Last Update Posted: 2024-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

(this list is not all inclusive)

• Male or female subjects between 18 and 65 years of age, inclusive at time of consent.
• Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview, using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-5, Clinical Trials Version [SCID-CT]).
• Subject must have a CGI-S score ≤ 4 (normal to moderately ill) at Screening
• Subject must have a PANSS total score ≤ 80 at Screening and a score of ≤ 4 on the following PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness)
• Subjects' antipsychotic medication at screening must have had no dose change (minor dose adjustments for tolerability purposes are permitted) for at least eight weeks prior to the Screening visit.

Read More

Exclusion Criteria

(this list is not all inclusive)

• Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia or intellectual disability (IQ < 70).

  • Subject has attempted suicide within 12 months prior to Screening.
  • Subject answers "yes" to "Suicidal Ideation" Items 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at Screening (ie. in the past 1 month) or at any subsequent C-SSRS assessment prior to dosing (ie, since last visit).
  • Subject is at risk of harming him/herself or others according to the Investigator's judgment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)	Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)	-
SEP-363856	SEP-363856	-

Primary Outcome Measures

Name	Time	Method
Gastric retention at 4 hr post-radiolabeled meal (gastric emptying scintigraphy (GES) imaging)	4 hours post-radiolabel meal on dosing Day 1 and 2	Gastric retention at 4 hr post-radiolabeled meal is gastric retention 4h post meal, which estimates a percentage of remaining gastric solids in the stomach 4 hours after the meal.
Gastric emptying T 1/2 (gastric emptying scintigraphy (GES) imaging)	multiple time-points post-radiolabelled meal on dosing day 1 and 2	Gastric emptying T 1/2 (gastric emptying scintigraphy (GES) imaging) is gastric emptying half life (T1/2), which is a time needed for the half of the ingested gastric solids to leave the stomach.

Secondary Outcome Measures

Name	Time	Method
Gastric retention (proportion retained or % retained) at 1 hr and 2 hr post-radiolabeled meal	1 and 2 hours post-radiolabel meal	Gastric retention (proportion retained or % retained) at 1h and 2h post meal.

Trial Locations

Locations (7)

Woodland Research Northwest, LLC; 🇺🇸 Rogers, Arkansas, United States

Woodland International Research Group; 🇺🇸 Little Rock, Arkansas, United States

Collaborative Neuroscience Research, LLC; 🇺🇸 Long Beach, California, United States

Research Centers of America; 🇺🇸 Oakland Park, Florida, United States

Pillar Clinical Research LLC; 🇺🇸 Richardson, Texas, United States

CNRI - San Diego, LLC; 🇺🇸 San Diego, California, United States

Galiz Research; 🇺🇸 Hialeah, Florida, United States